EVIDENT funds research to develop and validate objective FDA-ready clinical endpoints for emerging rapid-acting behavioral health therapies. It supports multimodal, longitudinal data collection from registered clinical trials involving interventions like neuroplastogens, neuromodulation, and digital therapeutics to improve therapy effectiveness identification and monitoring.
Eligibility criteria are not specified in the provided information.
